Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.82
- Piotroski Score 6.00
- Grade Market Perform
- Symbol (PNT)
- Company POINT Biopharma Global Inc.
- Price $12.50
- Changes Percentage (0.16%)
- Change $0.02
- Day Low $12.49
- Day High $12.51
- Year High $14.35
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/22/2024
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $17.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.10
- Trailing P/E Ratio 11.363636363636
- Forward P/E Ratio 11.363636363636
- P/E Growth 11.363636363636
- Net Income $98.29 M
Income Statement
Quarterly
Annual
Latest News of PNT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
SiriusPoint Ltd. (SPNT) Stock Price, News, Quote & History
SiriusPoint Ltd. reports strong financial results with a seventh consecutive quarter of underwriting profits and $109.9m in net income. The company's half-year core combined ratio improved to 92.5%, s...
By Yahoo! Finance | 1 week ago -
Investors in SiriusPoint (NYSE:SPNT) have seen favorable returns of 52% over the past three years
Investors can match market returns by buying index funds, but can potentially exceed them by investing in undervalued businesses. Analyzing SiriusPoint's performance shows a drop in earnings per share...
By Yahoo! Finance | 2 weeks ago -
Council Post: Lost In Space-Time: How Quantum A-PNT Can Save You
Paul Lipman is the Chief Revenue Officer at Infleqtion, spearheading growth and productization in quantum technology. Global Navigation Satellite Systems like GPS are crucial for various sectors, but ...
By Forbes | 2 months ago
